Prognostic significance of Wilms Tumor 1 (WT1) protein expression in breast cancer
Meme kanseri tüm dünyada kadınlarda görülen en sık kanser tipidir. Aynı klinikopatolojik evredeki kadınlarda meme kanserinin klinik seyri farklı olabilir, bu yüzden araştırmacılar tümör davranışını tahmin edebilmek için ek prognostik parametrelere odaklanmışlardır. Bu çalışmanın amacı, meme kanseri hastalarında tümör dokusunda Wilms Tumor 1 (WT1) ekspresyonunun prognostik önemi ve bunun bilinen prognostik değişkenlerle karşılaştırılmasıdır. Meme kanserli hastalarda, tümor ve tümör dokusu çevresindeki dokularda WT1 protein ekspresyonu ile prognostik faktörlerden yaş, patolojik tip, aksiller lenf nodu tutulumu, östrojen reseptör (ER) durumu, menopoz durumu, evre (TNM), tümör gradı ve tedavi arasındaki ilişki araştırıldı. WT1 monoklonal antikor (mAb) ile premenopozal durum arasında orta derecede bir ilişki saptandı (p=0.051). Ek olarak, tümör çevresindeki doku ile tümör gradı (p=0.045), evre (p=0.026), lenf nodu (p=0.026) ve aksiller tutulum (p=0.02) arasında anlamlı ilişki saptandı. Nükssüz sağkalım, nüks bölgeleri ile tümör dokusu ve tümör çevresi dokudaki WT1 mAb arasında anlamlı ilişki gözlenmedi (p=0.36). İnsan meme kanseri dokularında WT1 mAb gösterilmiştir ve bu çalışmada parafindeki doku örneklerine karşı monoklonal antikorlar kullanıldı. Bu sonuçlar premenopozal dönemde tümör dokusunda WT1 ekspresyonunun postmenopozal döneme göre daha fazla olduğunu göstermektedir. Bu sonuçların teyid edilmesi için meme kanserinde WT1 ekspresyonu için daha büyük çalışmalara ihtiyaç vardır.
Meme kanserinde Wilms Tümör 1 (WT1) protein ekspresyonunun prognostik önemi
Breast cancer is the most common cancer among women all over the world. Since the clinical outcome of breast cancer may differ among some women who have the same clinicopathological stage, researchers focused on additional prognostic parameters to predict the tumor behavior. The aim of this study was to investigate the prognostic value of Wilms Tumor 1 (WT1) expression in tumor tissues and to compare it with known prognostic variables in patients with breast cancer. In patients with breast cancer, we investigated the relationship between (WT1) protein expression in tumor and surrounding tissues and prognostic variables including age, pathologic type, axillary node involvement, estrogen receptor (ER) status, menopausal status, stage (TNM), tumor grade and treatment. Borderline significance was detected between WT1 monoclonal antibody (mAb) staining and premenopausal state (p=0.051). Additionally, surrounding tissue staining showed significant correlations with grade (p=0.045), stage (p=0.026), lymph node status (p=0.026), and axillary involvement (p=0.02), respectively. No correlation was demonstrated between relapse free survival, relapse sites and WT1 mAb staining of tumor and surrounding tissues (p=0.36). WT1 mAb staining was demonstrated in human breast cancer tissues, and in this study we have used monoclonal antibody against WT1 on paraffin-embedded tissue samples. The results indicate that WT1 expression by tumor is more evident in premenopausal state rather than postmenopausal period. To confirm the results, we need large scale studies on WT1 expression in breast cancer.
___
- 1. Gillmore R, Xue SA, Holler A, Kaeda J, Hadjiminas D, Healy
V, et al. Detection of Wilms' tumor antigen--specific CTL in
tumor-draining lymph nodes of patients with early breast
cancer. Clin Cancer Res 2006;12(1):34-42
- 2. Fisher B, Osborne CK, Margolese RG, Bloomer WD. Neoplasm
of the breast. In: Holland JF, Bast RC Jr, Morton DL, Frei E III,
Kufe DW, Weichselbaum RR (eds). Cancer Medicine,Williams
and Wilkins Co: International Edition, 1997: 2362-6
- 3. Hennessy C, Henry JA, May FE, Westley BR, Angus B,
Lennard TW. Expression of the antimetastatic gene nm23 in
human breast cancer: an association with good prognosis. J Natl
Cancer Inst 1991;83(4):281-5
- 4. Nemoto T, Natarajan N, Bedwani R, Vana J, Murphy GP
- Breast cancer in the medial half. Results of the 1978 national
survey of the American College of Surgeons. Cancer
1983;51(8):1333-8
- 5. Sauer T, Furu I, Beraki K, Jebsen PW, Ormerod E, Naess O
- nm23 protein expression in fine needle aspirates from breast
carcinoma: inverse correlation with cytologic grading, lymph
node status and ploidy. Cancer 1998;84(2):109-14
- 6. Thompson AM, Anderson TJ, Condie A, Prosser J, Chetty U,
Carter DC, et al. p53 allele losses, mutations and expressions in
breast cancer and their relationship to clinic-pathological
parameters. Int J Cancer 1992;50(4):528-32
- 7. Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, et al
- Expression of the Wilms' tumor gene WT1 in solid tumors and
its involvement in tumor cell growth. Jpn J Cancer Res
1999;90(2):194-204
- 8. Amin KM, Litzky LA, Smythe WR, Mooney AM, Morris JM,
Mews DJ, et al. Wilms’ tumor 1 susceptibility (WT1) gene
products are selectively expressed in malignant mesothelioma
- Am J Pathol 1995;146(2):344-56
- 9. Kumar-Singh S, Segers K, Rodeck U, Backhovens H, Bogers J,
Weyler J, et al. WT1 mutation in malignant mesothelioma and
WT1 immunoreactivity in relation to p53 and growth factor
receptor expression, cell-type transition, and prognosis. J Pathol
1997;181(1):67-74
- 10. Menssen HD, Renkl HJ, Rodeck U, Kari C, Schwartz S, Thiel
E. Detection of monoclonal antibodies of the Wilms’ tumor
(WT1) nuclear protein in patients with acute leukemia. Int J
Cancer 1997;70(5):518-23
- 11. Haber DA, Englert C, Maheswaran S. Functional propeties of
WT1. Med Pediatr Oncol 1996;27(5):453-5
- 12. Tsuboi A, Oka Y, Osaki T, Kumagai T, Tachibana I, Hayashi S,
et al. WT1 peptide-based immunotherapy for patients with lung
cancer: report of two cases. Microbiol Immunol
2004;48(3):175-84
- 13. Oji Y, Miyoshi Y, Koga S, Nakano Y, Ando A, Nakatsuka S, et
al. Overexpression of the Wilms' tumor gene WT1 in primary
thyroid cancer. Cancer Sci 2003;94(7):606-11
- 14. Oji Y, Inohara H, Nakazawa M, Nakano Y, Akahani S,
Nakatsuka S, et al. Overexpression of the Wilms' tumor gene
WT1 in head and neck squamous cell carcinoma. Cancer Sci
2003;94(6):523-9
- 15. Oji Y, Yamamoto H, Nomura M, Nakano Y, Ikeba A,
Nakatsuka S, et al. Overexpression of the Wilms' tumor gene
WT1 in colorectal adenocarcinoma. Cancer Sci 2003;94(8):712-7
- 16. Benjamin LE, Fredericks WJ, Barr FG, Rauscher FJ 3rd. Fusion
of the EWS1 and WT1 genes as a result of the
t(11;22)(p13;q12) translocation in desmoplastic small round cell
tumors. Med Pediatr Oncol 1996;27(5):434-9
- 17. Netinatsunthorn W, Hanprasertpong J, Dechsukhum C,
Leetanaporn R, Geater A. WT1 gene expression as a prognostic
marker in advanced serous epithelial ovarian carcinoma: an
immunohistochemical study. BMC Cancer. 2006;6:90
- 18. Tajinda K, Carrol J, Roberts CR Jr. Regulation of insulin-like
growth factor I receptor promoter activity by wild-type and
mutant version of the WT1 tumor suppressor. Endocrinology
1999;140(10):4713-24
- 19. Cooper MG. Tumor suppressor genes. The Cell:A Molecular
Approach, 1st edn, ASM press, 1997:626-7
- 20. Maheswaran S, Park S, Bernard A, Morris JF, Rauscher FJ 3d,
Hill DE, et al. Physical and functional interaction between WT1
and p53 proteins. Proc Natl Acad Sci USA 1993; 90(11):5100-4
- 21. Reizner N, Maor S, Sarfstein R, Abramovitch S, Welshons WV,
Curran EM, et al. The WT1 Wilms' tumor suppressor gene
product interacts with estrogen receptor-alpha and regulates
IGF-I receptor gene transcription in breast cancer cells. J Mol
Endocrinol 2005;35(1):135-44
- 22. Tuna M, Chavez-Reyes A, Tari AM. HER2/neu increases the
expression of Wilms' Tumor 1 (WT1) protein to stimulate Sphase
proliferation and inhibit apoptosis in breast cancer cells
- Oncogene 2005;24(9):1648-52
- 23. Miyoshi Y, Ando A, Egawa C, Taguchi T, Tamaki Y, Tamaki
H, et al. High expression of Wilms' tumor suppressor gene
predicts poor prognosis in breast cancer patients. Clin Cancer
Res 2002;8(5):1167-71
- 24. Renshaw J, Orr RM, Walton MI, Te Poele R, Williams RD,
Wancewicz EV, et al. Disruption of WT1 gene expression and
exon 5 splicing following cytotoxic drug treatment: antisense
down-regulation of exon 5 alters target gene expression and
inhibits cell survival. Mol Cancer Ther 2004;3(11):1467-84
- 25. Zapata-Benavides P, Tuna M, Lopez-Berestein G, Tari AM
- Downregulation of Wilms' tumor 1 protein inhibits breast
cancer proliferation. Biochem Biophys Res Commun
2002;295(4):784-90
- 26. Oji Y, Miyoshi Y, Kiyotoh E, Koga S, Nakano Y, Ando A, et al
- Absence of mutations in the Wilms' tumor gene WT1 in primary
breast cancer. Jpn J Clin Oncol 2004;34(2):74-7
- 27. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, et
al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T
lymphocytes by WT1 peptide vaccine and the resultant cancer
regression. Proc Natl Acad Sci USA 2004;101(38):13885-90
- 28. Morita S, Oka Y, Tsuboi A, Kawakami M, Maruno M, Izumoto
S, et al. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide
vaccine in patients with solid malignancy: safety assessment
based on the phase I data. Jpn J Clin Oncol 2006;36(4):231-6
- 29. Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B,
Buluwela L, et al. Wilms' tumor suppressor gene (WT1) is
expressed in primary breast tumors despite tumor-specific
promoter methylation. Cancer Res 2001;61(3):921-5
- 30. Silberstein GB, Van Horn K, Strickland P, Roberts CT Jr,
Daniel CW. Altered expression of the WT1 Wilms tumor
suppressor gene in human breast cancer. Proc Natl Acad Sci
USA 1997;94(15):8132-7.